NMD4C LetsTalkNMD webinar Exploring the clinical trial landscape in Duchenne muscular dystrophy: Challenges, opportunities and consideration of a possible cholesterol metabolism-related target, taking place Tuesday January 14, 2025. Presented by Dr Kathryn Selby and Dr Pascal Bernatchez.

Date

Jan 14 2025

Time

18:00 - 19:00

Labels

CPD-Accredited,
Virtual

CPD-Accredited Webinar | Exploring the clinical trial landscape in Duchenne muscular dystrophy: Challenges, opportunities and consideration of a possible cholesterol metabolism-related target

NMD4C and MDC are pleased to invite you to a webinar on Exploring the clinical trial landscape in Duchenne muscular dystrophy: Challenges, opportunities and consideration of a possible cholesterol metabolism-related target. NMD4C and MDC are providing organizational and technical support. This is a an independent clinical/academic webinar with no industry sponsorship or influence.

Register at: https://bit.ly/DMDUpdates2025

Speakers

  • Dr Kathryn Selby (Chair) | Clinical Assistant Professor, Pediatrics, University of British Columbia; Pediatric Neurologist, BC Children’s Hospital | Medical Director, Pediatric Neuromuscular Program of BC and the Yukon; Investigator, BC Children’s Hospital Research Institute
  • Dr Pascal Bernatchez | Associate Professor, Anesthesiology, Pharmacology and Therapeutics, University of British Columbia

Learning Objectives

  • To discuss and understand the present DMD clinical trial availability with consideration of age, mutation, ambulation and more
  • Challenges of implementation and access to treatments post clinical trials
  • Learn about the early metabolic comorbidities in human and animal models of DMD
  • Recognize that cholesterol metabolism may be altered in DMD
  • Learn about the similarities between DMD and statin-induced myopathy

The NMD Rounds & Educational Webinars is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

If you have any questions, please email <>

Tags: